Articles from Strand Therapeutics

Strand Therapeutics Inc., the programmable mRNA company developing curative therapies for cancer and beyond, will present preclinical data from its STX-003 program at the 2025 annual meetings of the American Association for Cancer Research (AACR) in Chicago April 25-30 and the American Society of Gene and Cell Therapy (ASGCT) in New Orleans May 13-17. The proof-of-concept studies demonstrate that Strand’s programmable mRNA genetic circuits can target the expression of interleukin-12 (IL-12) to cancerous tissue to help achieve the right therapeutic dose while reducing off target side effects. These groundbreaking findings underscore the potential of STX-003 and build on the promise of Strand’s platform and pipeline to address the critical challenges of solid tumor immunotherapy.

Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.

Strand Therapeutics, the programmable mRNA company developing breakthrough therapies for cancer and other diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of STX-001, a multi-mechanistic synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly into the tumor microenvironment.

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the appointment of Colleen Wilson as Chief People Officer. Ms. Wilson joins Strand with more than 23 years of leadership and operational experience in Human Resources, having led organizational effectiveness initiatives as well as establishing talent, culture, and diversity and inclusion engagement practices for both public and private life sciences companies.

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced today preclinical data from its programmable mRNA therapy STX-001, a multi-modal synthetic self-replicating mRNA technology that delivers a prolonged and locally-acting IL-12 cytokine to the tumor microenvironment.

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14 - 19, 2023 in Orlando, Florida.

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the appointment of Jay Stella, MBA as Chief Business Officer. He will establish and lead corporate and business development, and also be responsible for portfolio strategy, new product planning, and finance.

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced it has added an additional $45M to its Series A financing round, bringing the total amount raised in the Series A to $97 million. New investor FPV led the round, with participation from Eli Lilly and Company, Potentum Partners, and existing investors Playground Global, and a further unannounced syndicate.

Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, today announced that Prashant Nambiar, DVM, PhD, MBA has been appointed Senior Vice President, Research and Translational Development. With almost two decades in the pharmaceutical and biotechnology industry, Dr. Nambiar brings significant experience in drug discovery, pharmacology and translational development across different therapeutic areas and modalities.

Strand Therapeutics, a privately held biotech company developing next-generation, programmable mRNA therapeutics beyond vaccines, today announced that the company was awarded a Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an off-the-shelf chimeric antigen receptor T cell (CAR-T) immunotherapy based on the company’s mRNA technology for the treatment of B-cell non-Hodgkin’s lymphoma (NHL). The total funding amount awarded to Strand is approximately $400,000.

Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, today announced that the company was awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC). The total funding amount awarded to Strand is approximately $800,000.

Today, Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, announced Jake Becraft, PhD, co-founder and CEO of Strand, has been named to MIT Technology Review’s prestigious annual list of Innovators Under 35. Every year, the world-renowned media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world.

Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, today announced that the company raised $52 million in an oversubscribed Series A financing round syndicated by Redmile Group, BeiGene, Ltd., and Camford Capital, as well as existing investors Playground Global and ANRI. Strand has raised a total of $66 million to date.